Form 4: Koru Medical Systems CEO Receives Performance Stock Units

Koru Medical Systems, Inc. reports that President and CEO Adam R. Kalbermatten was granted performance stock units under his employment agreement.

Summary

• Adam R. Kalbermatten, President and CEO of Koru Medical Systems, Inc., was granted 286,697 Performance Stock Units (PSUs) on July 1, 2026.
• These PSUs are part of his amended and restated employment agreement.
• Vesting of these units is contingent upon achieving specific company performance targets.
• Specifically, 215,023 PSUs may vest based on the Company's net sales growth by December 31, 2030.
• An additional 71,674 PSUs may vest based on the Company's market capitalization by December 31, 2030.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on a standard executive compensation event (grant of performance stock units) without providing new financial results or significant strategic updates.

Positives

• Grant of performance stock units to the CEO, aligning executive compensation with company performance and long-term value creation.
• Specific performance metrics (net sales growth and market capitalization) are tied to vesting, indicating a focus on key business drivers.
• Long-term vesting horizons (up to December 31, 2030) suggest a commitment to sustained growth and shareholder value.

Negatives

• The grant is contingent on future performance, meaning the CEO may not receive the full award if targets are not met.
• The filing does not provide current financial performance data or projections, making it difficult to assess the likelihood of vesting.

Risks

• Failure to achieve targeted net sales growth by December 31, 2030, could result in the forfeiture of 215,023 PSUs.
• Failure to achieve targeted market capitalization by December 31, 2030, could result in the forfeiture of 71,674 PSUs.
• The value of the PSUs is subject to market fluctuations and the overall performance of Koru Medical Systems, Inc.

Future Outlook

The future outlook for the performance stock units is dependent on the company achieving specific net sales growth targets by December 31, 2030, and market capitalization targets by December 31, 2030. The actual vesting of these units will be determined by these future performance outcomes.

Management Comments

• The filing of this statement shall not be construed as an admission (a) that the person filing this statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this statement, or (b) that this statement is legally required to be filed by such person.

Industry Context

StockSavvy.ai notes that the granting of performance stock units to senior executives is a common practice in the medical technology sector, designed to incentivize long-term growth and align executive interests with those of shareholders. The specific metrics chosen (net sales growth and market capitalization) are standard indicators of success in this industry.

Stakeholder Impact

• Shareholders: The grant aligns executive incentives with long-term company performance, potentially leading to increased shareholder value if targets are met. However, the value of these units is not realized unless performance goals are achieved.
• Employees: The CEO's focus on sales growth and market capitalization may indirectly benefit employees through company expansion and success.
• Management: The CEO's compensation is directly tied to achieving specific performance milestones.

Next Steps

• Monitor Koru Medical Systems, Inc.'s net sales growth and market capitalization performance leading up to December 31, 2030.
• Observe future SEC filings for any updates on the vesting status of these performance stock units.

Key Dates

Keywords

Form 4, SEC Filing, Koru Medical Systems, KRMD, Adam R. Kalbermatten, Performance Stock Units, PSU, Executive Compensation, Stock Options, Net Sales Growth, Market Capitalization, Employment Agreement